Go Back

Biodesix to Present at Leerink Partners 5th Annual Global Healthcare Conference

Biodesix, Inc. today announced that its Chief Executive Officer, David Brunel, is scheduled to present a corporate overview on “Deep Phenotyping, Machine Learning to Precision Medicine” during the Leerink Partners 5th Annual Global Healthcare Conference at the Waldorf Astoria, New York, from February 10-11, 2016. Biodesix’ presentation is scheduled for February 11 at 11:10AM ET. Mr. Brunel will be available for one-on-one meetings during the conference.


Biodesix, VeriStrat and GeneStrat are trademarks or registered trademarks of Biodesix, Inc.  All other trademarks referenced herein are property of their respective owners.


About Biodesix
Biodesix® is a molecular diagnostics company advancing the development of innovative blood-based tests in oncology to enable precision medicine. Biodesix discovers, develops and commercializes multivariate protein and genomic diagnostic blood tests, including GeneStrat™ and VeriStrat®, that deliver results within 72 hours. The company is changing the standard of care by providing physicians with diagnostic tests for better therapeutic guidance, more accurate prognosis and enhanced disease monitoring to improve patient outcomes. At the forefront of precision medicine, Biodesix is developing new blood tests to identify patients who may benefit from immunotherapies. In addition to developing novel diagnostics independently, the company partners with biotechnology and pharmaceutical companies to develop companion diagnostics for use with therapeutic agents.


Topics: Press Releases, Leerink conference